Table 1 Baseline characteristics of the studies included
Study | Treatment | Sample size | Age (year) | Female/male | Underlying disease (n) | Steroid dosage (mg/day) (prednisolone) | Steroid duration (months) | Follow-up (months) |
|---|---|---|---|---|---|---|---|---|
Mok 2015 [17] | Denosumab | 21 | 54.9 ± 12.8 | 21/0 | Systemic lupus erythematosus (17) Rheumatoid arthritis (4) | 4.60 ± 2.06 | 108.2 ± 56.0 | 12 |
Bisphosphonates (unidentified) | 21 | 54.6 ± 13.4 | 21/0 | Systemic lupus erythematosus (15) Rheumatoid arthritis (6) | 4.12 ± 2.14 | 94.1 ± 75.6 | 12 | |
Iseri 2018 [18] | Denosumab | 14 | 66.5 (39.0–75.8) | 6/8 | MCNS (4),Lupus nephritis (3), MN (2), ANCA-GN (3), FSGS (1), IgAN (1), HSPN (0) | 5.0 (2.4–8.5) | 82.8 (26.4–228) | 12 |
Alendronate | 14 | 65.5 (45.0–78.5) | 6/8 | MCNS (5),Lupus nephritis (4), MN (3), ANCA-GN (0), FSGS (1), IgAN (0), HSPN (1) | 5.0 (2.5–9.3) | 108 (21.6–229.2) | 12 | |
Saag 2019 [12] | Denosumab | 253 | 61.5 ± 11.6 | 185/68 | Rheumatologic disorders (173), Respiratory disorders (46), Inflammatory bowel disease (3), Sarcoidosis (4), Neurologic disorders (11), Dermatologic disorders (9), Other (46) | 12.3 ± 8.09 | 0–3: 5.1% 3–12: 32.0% ≥12: 62.5% | 24 |
Resedronate | 252 | 61.3 ± 11.1 | 185/67 | Rheumatologic disorders (184), Respiratory disorders (37), Inflammatory bowel disease (5), Sarcoidosis (5), Neurologic disorders (15), Dermatologic disorders (8), Other (37) | 11.1 ± 7.69 | 0–3: 3.2%, 3–12: 29.8% ≥ 12: 66.3% | 24 | |
Mok 2021 [19] | Denosumab | 69 | 52.0 ± 12.3 | 68/1 | systemic lupus erythematosus (81%), rheumatoid arthritis (9.4%), inflammatory myopathies (5%), systemic vasculitis (3.8%) | 5.1 ± 2.9 | 111 ± 62 | 12 |
Alendronate | 70 | 48.0 ± 12.9 | 65/5 | 5.0 ± 2.4 | 104 ± 69 | 12 |